NO783153L - Nytt partikkelmateriale samt fremstilling og anvendelse derav, spesielt som medikament - Google Patents

Nytt partikkelmateriale samt fremstilling og anvendelse derav, spesielt som medikament

Info

Publication number: NO783153L
Authority: NO; Norway
Prior art keywords: ganglioside; particles; cholera; hematin; suspension
Prior art date: 1977-09-19

Application number

NO783153A

Other languages

English (en)

Norwegian (no)

Inventor

Jean-Louis Tayot

Marie-Claude Mynard

Original Assignee

Merieux Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-09-19

Filing date

1978-09-18

Publication date

1979-03-20

1978-09-18 Application filed by Merieux Inst filed Critical Merieux Inst

1979-03-20 Publication of NO783153L publication Critical patent/NO783153L/no

Links

239000002245 particle Substances 0.000 title claims description 72
239000000463 material Substances 0.000 title claims description 13
238000004519 manufacturing process Methods 0.000 title claims description 8
150000002270 gangliosides Chemical class 0.000 claims description 74
229920001282 polysaccharide Polymers 0.000 claims description 62
150000004676 glycans Chemical class 0.000 claims description 61
239000005017 polysaccharide Substances 0.000 claims description 61
102000009016 Cholera Toxin Human genes 0.000 claims description 55
108010049048 Cholera Toxin Proteins 0.000 claims description 54
238000000034 method Methods 0.000 claims description 44
BMUDPLZKKRQECS-UHFFFAOYSA-K 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid iron(3+) hydroxide Chemical compound [OH-].[Fe+3].[N-]1C2=C(C)C(CCC(O)=O)=C1C=C([N-]1)C(CCC(O)=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 BMUDPLZKKRQECS-UHFFFAOYSA-K 0.000 claims description 34
229940109738 hematin Drugs 0.000 claims description 34
239000000725 suspension Substances 0.000 claims description 33
229910052500 inorganic mineral Inorganic materials 0.000 claims description 30
239000011707 mineral Substances 0.000 claims description 30
206010008631 Cholera Diseases 0.000 claims description 25
239000011236 particulate material Substances 0.000 claims description 25
239000003053 toxin Substances 0.000 claims description 20
231100000765 toxin Toxicity 0.000 claims description 20
108700012359 toxins Proteins 0.000 claims description 20
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 17
239000011248 coating agent Substances 0.000 claims description 17
238000000576 coating method Methods 0.000 claims description 17
241000607598 Vibrio Species 0.000 claims description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
206010047400 Vibrio infections Diseases 0.000 claims description 15
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 13
210000003743 erythrocyte Anatomy 0.000 claims description 10
230000001580 bacterial effect Effects 0.000 claims description 8
229910052799 carbon Inorganic materials 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 7
229960005486 vaccine Drugs 0.000 claims description 6
244000052616 bacterial pathogen Species 0.000 claims description 5
239000000969 carrier Substances 0.000 claims description 5
229920000620 organic polymer Polymers 0.000 claims description 5
241001465754 Metazoa Species 0.000 claims description 4
229940079593 drug Drugs 0.000 claims description 4
230000007062 hydrolysis Effects 0.000 claims description 3
238000006460 hydrolysis reaction Methods 0.000 claims description 3
239000000178 monomer Substances 0.000 claims description 2
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
229920002554 vinyl polymer Polymers 0.000 claims description 2
MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims 2
KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 claims 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims 2
238000010306 acid treatment Methods 0.000 claims 1
239000004480 active ingredient Substances 0.000 claims 1
125000002421 ganglioside group Chemical group 0.000 claims 1
239000000243 solution Substances 0.000 description 37
229920000642 polymer Polymers 0.000 description 26
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
239000002504 physiological saline solution Substances 0.000 description 14
229920002678 cellulose Polymers 0.000 description 12
238000005119 centrifugation Methods 0.000 description 12
229920002307 Dextran Polymers 0.000 description 11
239000001913 cellulose Substances 0.000 description 11
238000011534 incubation Methods 0.000 description 11
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
239000000872 buffer Substances 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 8
230000036039 immunity Effects 0.000 description 8
239000000047 product Substances 0.000 description 8
241000283973 Oryctolagus cuniculus Species 0.000 description 7
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
229920002472 Starch Polymers 0.000 description 7
150000001299 aldehydes Chemical group 0.000 description 7
-1 amine function ion Chemical class 0.000 description 7
230000006870 function Effects 0.000 description 7
QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 description 7
239000000203 mixture Substances 0.000 description 7
238000007254 oxidation reaction Methods 0.000 description 7
239000011780 sodium chloride Substances 0.000 description 7
235000019698 starch Nutrition 0.000 description 7
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
238000005904 alkaline hydrolysis reaction Methods 0.000 description 6
239000000706 filtrate Substances 0.000 description 6
239000004816 latex Substances 0.000 description 6
229920000126 latex Polymers 0.000 description 6
230000003647 oxidation Effects 0.000 description 6
239000000843 powder Substances 0.000 description 6
239000008107 starch Substances 0.000 description 6
238000005406 washing Methods 0.000 description 6
229920002491 Diethylaminoethyl-dextran Polymers 0.000 description 5
125000003047 N-acetyl group Chemical group 0.000 description 5
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
238000010168 coupling process Methods 0.000 description 5
238000004132 cross linking Methods 0.000 description 5
238000005470 impregnation Methods 0.000 description 5
239000007788 liquid Substances 0.000 description 5
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 5
229910052814 silicon oxide Inorganic materials 0.000 description 5
239000000126 substance Substances 0.000 description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
125000000217 alkyl group Chemical group 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
239000003431 cross linking reagent Substances 0.000 description 4
238000001035 drying Methods 0.000 description 4
229960004279 formaldehyde Drugs 0.000 description 4
235000019256 formaldehyde Nutrition 0.000 description 4
229920002521 macromolecule Polymers 0.000 description 4
239000011148 porous material Substances 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
238000006722 reduction reaction Methods 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
230000002588 toxic effect Effects 0.000 description 4
229920000936 Agarose Polymers 0.000 description 3
239000005995 Aluminium silicate Substances 0.000 description 3
241001494479 Pecora Species 0.000 description 3
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
235000012211 aluminium silicate Nutrition 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
125000002091 cationic group Chemical group 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
150000002148 esters Chemical group 0.000 description 3
239000011521 glass Substances 0.000 description 3
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 3
230000000737 periodic effect Effects 0.000 description 3
229910021426 porous silicon Inorganic materials 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000009467 reduction Effects 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
150000004760 silicates Chemical class 0.000 description 3
239000012279 sodium borohydride Substances 0.000 description 3
229910000033 sodium borohydride Inorganic materials 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 2
SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 2
BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 2
MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
239000003513 alkali Substances 0.000 description 2
125000000129 anionic group Chemical group 0.000 description 2
239000006286 aqueous extract Substances 0.000 description 2
WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 2
150000002118 epoxides Chemical class 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
239000000395 magnesium oxide Substances 0.000 description 2
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
229910044991 metal oxide Inorganic materials 0.000 description 2
150000004706 metal oxides Chemical class 0.000 description 2
210000004400 mucous membrane Anatomy 0.000 description 2
230000001590 oxidative effect Effects 0.000 description 2
LIVNPJMFVYWSIS-UHFFFAOYSA-N silicon monoxide Chemical class [Si-]#[O+] LIVNPJMFVYWSIS-UHFFFAOYSA-N 0.000 description 2
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000010186 staining Methods 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000005199 ultracentrifugation Methods 0.000 description 2
238000002255 vaccination Methods 0.000 description 2
RJBDSRWGVYNDHL-XNJNKMBASA-N (2S,4R,5S,6S)-2-[(2S,3R,4R,5S,6R)-5-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[(2R,3S,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(E,2R,3S)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-5-amino-6-[(1S,2R)-2-[(2S,4R,5S,6S)-5-amino-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3-dihydroxypropyl]-4-hydroxyoxane-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3NC(C)=O)[C@H](O[C@@]3(C[C@@H](O)[C@H](N)[C@H](O3)[C@H](O)[C@@H](CO)O[C@@]3(C[C@@H](O)[C@H](N)[C@H](O3)[C@H](O)[C@H](O)CO)C(O)=O)C(O)=O)[C@H]2O)[C@H](O)[C@H]1O)[C@@H](O)\C=C\CCCCCCCCCCCCC RJBDSRWGVYNDHL-XNJNKMBASA-N 0.000 description 1
XSHWKULGRFTYIT-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;buta-1,3-diene;styrene Chemical compound C=CC=C.C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C XSHWKULGRFTYIT-UHFFFAOYSA-N 0.000 description 1
HPILSDOMLLYBQF-UHFFFAOYSA-N 2-[1-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COC(CCC)OCC1CO1 HPILSDOMLLYBQF-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
241000272517 Anseriformes Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
208000036632 Brain mass Diseases 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
241000272201 Columbiformes Species 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
241000283086 Equidae Species 0.000 description 1
235000014755 Eruca sativa Nutrition 0.000 description 1
244000024675 Eruca sativa Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
238000004026 adhesive bonding Methods 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000001147 anti-toxic effect Effects 0.000 description 1
239000003637 basic solution Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
244000309466 calf Species 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001728 carbonyl compounds Chemical class 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
238000012412 chemical coupling Methods 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
230000007123 defense Effects 0.000 description 1
125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
230000029087 digestion Effects 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 1
150000003944 halohydrins Chemical class 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
230000002949 hemolytic effect Effects 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
125000001183 hydrocarbyl group Chemical group 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
150000002466 imines Chemical class 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
230000000951 immunodiffusion Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
JEHCHYAKAXDFKV-UHFFFAOYSA-J lead tetraacetate Chemical compound CC(=O)O[Pb](OC(C)=O)(OC(C)=O)OC(C)=O JEHCHYAKAXDFKV-UHFFFAOYSA-J 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229920005615 natural polymer Polymers 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000011146 organic particle Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
150000004804 polysaccharides Polymers 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
150000003138 primary alcohols Chemical group 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000005956 quaternization reaction Methods 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
239000004627 regenerated cellulose Substances 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000013049 sediment Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000010703 silicon Substances 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
239000012905 visible particle Substances 0.000 description 1
239000003643 water by type Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/107—Vibrio
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6006—Cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)

NO783153A 1977-09-19 1978-09-18 Nytt partikkelmateriale samt fremstilling og anvendelse derav, spesielt som medikament NO783153L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR7728162A FR2403081A1 (fr)	1977-09-19	1977-09-19	Nouveau materiau particulaire, sa preparation et son application, notamment comme medicament

Publications (1)

Publication Number	Publication Date
NO783153L true NO783153L (no)	1979-03-20

Family

ID=9195521

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO783153A NO783153L (no)	1977-09-19	1978-09-18	Nytt partikkelmateriale samt fremstilling og anvendelse derav, spesielt som medikament

Country Status (12)

Country	Link
US (1)	US4303638A (fr)
JP (1)	JPS5455718A (fr)
BE (1)	BE870564A (fr)
CH (1)	CH633447A5 (fr)
DE (1)	DE2840506A1 (fr)
DK (1)	DK411378A (fr)
FR (1)	FR2403081A1 (fr)
GB (1)	GB2004186B (fr)
IT (1)	IT1174425B (fr)
NL (1)	NL7809485A (fr)
NO (1)	NO783153L (fr)
SE (1)	SE7809788L (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0016702B1 (fr) *	1979-03-16	1985-02-20	Institut Merieux	Médicament, notamment pour le traitement du choléra, et compositions pharmaceutiques le contenant
FR2478104B1 (fr) *	1980-03-17	1986-08-08	Merieux Inst	Nouveaux derives de gangliosides, leur preparation et leur application
US4356170A (en) *	1981-05-27	1982-10-26	Canadian Patents & Development Ltd.	Immunogenic polysaccharide-protein conjugates
US4493825A (en) *	1982-10-05	1985-01-15	Iowa State University Research Foundation	Purified and antigenically selective vaccines for domestic animals
US4507472A (en) *	1983-06-14	1985-03-26	Usher Thomas C	Manufacture of diethylaminoethyl dextrans
IL69558A (en) *	1983-08-23	1988-06-30	Yeda Res & Dev	Synthetic cholera vaccine
US5912017A (en) *	1987-05-01	1999-06-15	Massachusetts Institute Of Technology	Multiwall polymeric microspheres
DD298884A5 (de) *	1990-07-10	1992-03-19	Charite Der Humboldt-Universitaet,De	Impfstoffe gegen virale antigene und verfahren zu ihrer herstellung
DE4141970C2 (de) *	1991-12-16	1998-02-19	Charite Med Fakultaet	Kombinationsimpfstoff gegen AIDS, Bilharziose und Tuberkulose und Verfahren zu seiner Herstellung
US5380522A (en) *	1992-08-11	1995-01-10	Day; Charles E.	Method for treatment of irritable bowel syndrome
US5502042A (en) *	1994-07-22	1996-03-26	United States Surgical Corporation	Methods and compositions for treating wounds
SE9600648D0 (sv) *	1996-02-21	1996-02-21	Bror Morein	Receptorbimdande enhet
US5943983A (en) *	1996-08-15	1999-08-31	The United States Of America As Represented By The Secretary Of The Air Force	Non-human primate research support tilt table
US6576244B1 (en) *	1998-06-19	2003-06-10	Acambis, Inc.	LT and CT in parenteral immunization methods against helicobacter infection
US20080112933A1 (en) *	2004-11-08	2008-05-15	Scadden David T	Methods and Compositions for Increasing Stem Cell Homing Using Gas Activators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2143088A (en) *	1937-05-28	1939-01-10	George E Rockwell	Therapeutic agent
US2952585A (en) *	1957-06-19	1960-09-13	New England Inst For Medical R	Immunizing against and treatment of diseases
US3185625A (en) *	1961-11-08	1965-05-25	Brown Ethan Allan	Injectionable substances
GB1452648A (en) *	1973-11-21	1976-10-13	American Home Prod	Cholera toxoid
US4125492A (en) *	1974-05-31	1978-11-14	Pedro Cuatrecasas	Affinity chromatography of vibrio cholerae enterotoxin-ganglioside polysaccharide and the biological effects of ganglioside-containing soluble polymers
AR215459A1 (es) *	1976-04-02	1979-10-15	Brewer J	Metodo para producir un agente terapeutico capaz de proporcionar una marca en un animal no humano para indicar la administracion del agente al animal y para proporcionar tambien un repositorio del agente a ser libeberado durante un espacio de tiempo

1977
- 1977-09-19 FR FR7728162A patent/FR2403081A1/fr active Granted
1978
- 1978-09-18 IT IT27801/78A patent/IT1174425B/it active
- 1978-09-18 DK DK411378A patent/DK411378A/da unknown
- 1978-09-18 NL NL7809485A patent/NL7809485A/xx not_active Application Discontinuation
- 1978-09-18 CH CH970178A patent/CH633447A5/fr not_active IP Right Cessation
- 1978-09-18 SE SE7809788A patent/SE7809788L/xx unknown
- 1978-09-18 NO NO783153A patent/NO783153L/no unknown
- 1978-09-18 GB GB7837186A patent/GB2004186B/en not_active Expired
- 1978-09-18 DE DE19782840506 patent/DE2840506A1/de not_active Ceased
- 1978-09-18 BE BE190555A patent/BE870564A/fr not_active IP Right Cessation
- 1978-09-19 JP JP11504578A patent/JPS5455718A/ja active Pending
- 1978-09-19 US US05/944,122 patent/US4303638A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
NL7809485A (nl)	1979-03-21
DE2840506A1 (de)	1979-03-29
JPS5455718A (en)	1979-05-04
FR2403081B1 (fr)	1981-08-21
GB2004186A (en)	1979-03-28
SE7809788L (sv)	1979-03-20
BE870564A (fr)	1979-03-19
IT1174425B (it)	1987-07-01
CH633447A5 (fr)	1982-12-15
IT7827801A0 (it)	1978-09-18
US4303638A (en)	1981-12-01
FR2403081A1 (fr)	1979-04-13
DK411378A (da)	1979-03-20
GB2004186B (en)	1982-07-14

Publication	Publication Date	Title
NO783153L (no)	1979-03-20	Nytt partikkelmateriale samt fremstilling og anvendelse derav, spesielt som medikament
US4220717A (en)	1980-09-02	Isolation and purification of polyribosyl ribitol phosphate from Haemophilus influenzae type b.
US4308254A (en)	1981-12-29	Material able to fix reversibly biologial macromolecules, its preparation and its application
US5410025A (en)	1995-04-25	Unmodified intravenously administered immunoglobulin preparations containing immunoglobulin M and/or A
NO840341L (no)	1984-08-01	Fremgangsmaate ved fremstilling av koplet h-influensa type b-vaksine
DK161013B (da)	1991-05-21	Fremgangsmaade til fremstilling af et vandoploeseligt covalent polysaccharid-diphtheria-toxoid-konjugat samt hapten, i det vaesentlige frit for protein og nucleinsyre, til anvendelse ved fremgangsmaaden
Springer et al.	1965	Cross reactive human blood-group H (O) specific polysaccharide from Sassafras albidum and characterization of its hapten
Bricknell et al.	1997	Antibody response and protection of Atlantic salmon (Salmo salar) immunised with an extracellular polysaccharide ofAeromonas salmonicida
EP0527753A1 (fr)	1993-02-24	Purification de la membrane externe d'une proteine de la coqueluche.
Klipstein et al.	1977	Immunological interrelationships between cholera toxin and the heat-labile and heat-stable enterotoxins of coliform bacteria
JPH11507805A (ja)	1999-07-13	非細胞性百日咳ワクチンおよびその製造方法
Wu-Yuan et al.	1977	Architecture and chemistry of microconidial walls of Trichophyton mentagrophytes
US4239749A (en)	1980-12-16	Neisseria gonorrhoeae vaccine
KR20030096369A (ko)	2003-12-24	저분자량 하이알루론산과 폴리펩티드 독소의 면역원성접합체
CN1709505B (zh)	2010-06-16	多价细菌荚膜多糖-蛋白质结合物联合疫苗
JP2563797B2 (ja)	1996-12-18	ボルデテラ属細菌の蛋白質抗原の精製方法
US3600378A (en)	1971-08-17	Method for the purification of lipopolysaccharides
GB2182937A (en)	1987-05-28	Common antigen (psc-a)to pseudomonas aeruginosa
JP4091136B2 (ja)	2008-05-28	免疫賦活剤
WO2007035341A1 (fr)	2007-03-29	Production et purification de proteine a sans utilisation de composants d'origine animale
Ihara et al.	1982	Physicochemical properties of a new bactericidal factor, Ra-reactive factor
CN115161207A (zh)	2022-10-11	半乳糖酵母液的制备方法、半乳糖酵母粉及在亮肤淡化皱纹的应用
Lindahl et al.	1986	Binding to erythrocyte membrane glycoproteins and carbohydrate specificity of F41 fimbriae of enterotoxigenic Escherichia coli
NO149611B (no)	1984-02-13	Fremgangsmaate for isolering og rensning av immunologisk aktivt polyribosyl-ribitolfosfat (prp), det kapsulaere polysakkarid av haemophilus influenzae
CN115006522B (zh)	2025-08-22	一种双价痢疾结合物组合疫苗的制备方法